Curculigoside suppresses glioblastoma progression through the EGFR/MMP2 axis: evidence from network pharmacology and experimental validation.
Glioblastoma (GBM) is an aggressive primary brain tumor characterized by rapid progression, therapeutic resistance, and poor clinical outcomes. Curculigoside (CUR), a natural compound with anti-inflammatory and antitumor properties, has not been systematically investigated in GBM. This study aimed to investigate the an...